Business · 11/10/2024Updated: 10/17/2026 · 1 min read
FDA Approves TREMFYA (guselkumab) Product Under Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved a product redeeming a priority review voucher for TREMFYA (guselkumab), a treatment for a rare pediatric disease, following a review of its supplemental application submitted on September 11, 2024.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →